Life Technologies (LIFE) Signs Patent Licensing Agreement with with iPS Academia Japan for Stem Cell Technology

Article Stock Quotes (1) Comments (0)

Life Technologies Corporation (NASDAQ: LIFE) has deepened its commitment to stem cell research and its customers by signing a non-exclusive agreement with iPS Academia Japan for its induced pluripotent stem (iPS) cell patent portfolio. The worldwide license will enable Life Technologies, a leading provider of innovative life science solutions, to expand its range of products and services for the iPS cell research community.

By leveraging its expertise in stem cell tool manufacturing and its global distribution network, Life Technologies is now positioned to develop and commercialize products designed to create iPS cells and differentiate them into any cell type for use in drug discovery and pre-clinical research. In additional to directly selling iPS cells, the license enables the company to provide iPS cell creation, differentiation and screening services for scientists around the world.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• CLSA Downgrades Life Technologies (LIFE) to Underperform
• Sanofi (SNY), Regeneron (REGN) Report Publication of Positive Dupilumab Phase 2a Data
• UPDATE: Senate Takes Aim at Apple (AAPL); Says Irish Unit Earned $22B, Paid $10M in Taxes

Create E-mail Alert Related Categories

Corporate News

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?